Year: 2025

Genetic toxicology remains one of the most critical and consequential endpoints in the safety evaluation of pharmaceuticals. Recent scientific discussions within the toxicology community have highlighted how genetic toxicology assessments are strategically applied across early screening, regulatory development, and emerging impurity-related challenges. These discussions underscore evolving regulatory expectations, advances in testing strategies, and practical pathways…

New Approach Methodologies (NAMs) are steadily influencing modern toxicology and chemical risk evaluation, offering alternatives that reduce reliance on traditional testing strategies. While enthusiasm around these tools is increasing, researchers caution that premature declarations of success may create unrealistic expectations about their current capabilities. Scientific observers note that when bold claims are made before the…

For decades, LDL cholesterol (LDL-C) was considered the primary marker for assessing heart disease risk. But emerging scientific insights show that relying on LDL-C alone paints only part of the picture, sometimes a misleading one. Today, cardiologists and researchers emphasize that heart disease is better understood through particle numbers rather than just cholesterol content. A…